Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
Glycopyrronium bromide
Proveca Pharma Limited
A03AB02
glycopyrronium
Drugs for functional gastrointestinal disorders
Sialorrhea
Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
Revision: 10
Authorised
2016-09-15
25 B. PACKAGE LEAFLET 26 PACKAGE LEAFLET: INFORMATION FOR THE USER SIALANAR 320 MICROGRAMS/ML ORAL SOLUTION glycopyrronium READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOUR CHILD STARTS TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as your child’s. − If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Sialanar is and what it is used for 2. What you need to know before you give Sialanar 3. How to use Sialanar 4. Possible side effects 5. How to store Sialanar 6. Contents of the pack and other information 1. WHAT SIALANAR IS AND WHAT IT IS USED FOR Sialanar contains the active substance glycopyrronium. Glycopyrronium belongs to a group of medicines known as quaternary ammonium anticholinergics, which are agents that block or reduce the transmission between nerve cells. This reduced transmission can de-activate the cells that produce saliva. Sialanar is used to treat excessive production of saliva (sialorrhoea) in children and adolescents aged 3 years and older. Sialorrhoea (drooling or excessive salivation) is a common symptom of many diseases of the nerves and muscles. It is mostly caused by poor control of muscles in the face. Acute sialorrhoea may be associated with inflammation, dental infections or infections of the mouth. Sialanar acts on the salivary glands to reduce production of saliva. 2. WHAT YOU NEED TO KNOW BEFORE YOU GIVE SIALANAR DO NOT GIVE SIALANAR IF YOUR CHILD OR ADOLESCENT: − is allergic to glycopyrronium or any of the other ingredients of this medicine (listed in section 6) − is pregnant or breast feeding − has glaucoma (raised pressure in the eye) − is unable Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Sialanar 320 micrograms/ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 400 micrograms of glycopyrronium bromide equivalent to 320 micrograms of glycopyrronium. Excipient(s) with known effect Each ml contains 2.3 mg sodium benzoate (E211). For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Oral solution Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Sialanar should be prescribed by physicians experienced in the treatment of paediatric patients with neurological disorders. Posology Due to the lack of long term safety data, Sialanar is recommended for short -term intermittent use (see section 4.4). _Paediatric population – children and adolescents aged 3 years and older _ The dosing schedule for glycopyrronium is based on the weight of the child, starting with approximately 12.8 micrograms/kg per dose (equivalent to 16 micrograms/kg per dose glycopyrronium bromide), three times per day and increasing by the doses shown in Table 1 below, every 7 days. Dose titration should be continued until efficacy is balanced with undesirable effects and amended up or down as appropriate, to a maximum individual dose of 64 micrograms/kg body weight glycopyrronium or 6 ml (1.9 mg glycopyrronium, equivalent to 2.4 mg glycopyrronium bromide) three times a day, whichever is less. Dose titrations should be conducted in discussion with the carer to assess both efficacy and undesirable effects until an acceptable maintenance dose is achieved. Undesirable effects may be minimised by using the lowest effective dose necessary to control symptoms. It is important that the carer checks the dose volume in the syringe before administration. The maximum volume of the highest dose Aqra d-dokument sħiħ